Contract Research
Contract Research reports are the public domain output of consultancy projects that are published with the clients permission when the content is of interest to a wide audience.
Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
11 July 2023
This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted by dementia, and the economic benefits arising from dementia research in the UK.
Investment in dementia research and medicine research and development (R&D) is significantly lower in comparison to other diseases such as cancer. However, recent breakthroughs and growing R&D pipeline show that this area has high potential for research over the next years. It is, therefore, important to estimate the benefits of dementia research to patients, their carers, the economy, and society.
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.
Navigating the Landscape of Digital Health – United Kingdom
16 December 2022
Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.
Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
30 November 2022
An increasingly common strategy for treating many cancers is to utilise several medicines with distinct but complementary mechanisms of action in combination or in close sequence…
Supporting the Era of Green Pharmaceuticals in the UK
1 November 2022
This report sets out the high-priority activities that the NHS, UK government and industry should undertake to tackle the challenge of reducing the NHS’s carbon footprint.